{"id":"https://openalex.org/W2741532736","doi":"https://doi.org/10.1158/1538-7445.am2017-5098","title":"Abstract 5098: NG-348: a novel oncolytic virus designed to mediate anti-tumour activity via the potent and selective polyclonal activation of tumor-infiltrating T-cells","display_name":"Abstract 5098: NG-348: a novel oncolytic virus designed to mediate anti-tumour activity via the potent and selective polyclonal activation of tumor-infiltrating T-cells","publication_year":2017,"publication_date":"2017-07-01","ids":{"openalex":"https://openalex.org/W2741532736","doi":"https://doi.org/10.1158/1538-7445.am2017-5098","mag":"2741532736"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2017-5098","doi":"https://doi.org/10.1158/1538-7445.am2017-5098","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2017-5098","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048180481","display_name":"BRIAN R. CHAMPION","orcid":"https://orcid.org/0000-0003-3860-9842","observed_orcids":["https://orcid.org/0000-0003-3860-9842"]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Brian R. Champion","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051279530","display_name":"Matthieu Besneux","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Matthieu Besneux","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046169571","display_name":"Nalini Marino","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Nalini Marino","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Darren Plumb","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Darren Plumb","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035714942","display_name":"Prithvi Kodialbail","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Prithvi Kodialbail","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026184651","display_name":"Sam Illingworth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sam Illingworth","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091753055","display_name":"Rochelle Lear","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rochelle Lear","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041595076","display_name":"Alice Brown","orcid":"https://orcid.org/0000-0003-4770-346X","observed_orcids":["https://orcid.org/0000-0003-4770-346X"]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alice C. Brown","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom","institution_ids":["https://openalex.org/I4210102991"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210102991"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"77","issue":"13_Supplement","first_page":"5098","last_page":"5098"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.006500000134110451,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12996","display_name":"Bacterial Cancer Therapy","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1305","display_name":"Biotechnology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oncolytic-adenovirus","display_name":"oncolytic adenovirus","score":0.9599999785423279},{"id":"https://openalex.org/keywords/cd80","display_name":"CD80","score":0.7440000176429749},{"id":"https://openalex.org/keywords/okt3","display_name":"OKT3","score":0.7540000081062317},{"id":"https://openalex.org/keywords/cd3e","display_name":"CD3\u03b5","score":0.574999988079071},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.7210000157356262},{"id":"https://openalex.org/keywords/tumor-infiltrating-t-cells","display_name":"tumor-infiltrating T cells","score":0.8970000147819519},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.6610000133514404},{"id":"https://openalex.org/keywords/t-cell-costimulation","display_name":"T cell costimulation","score":0.6039999723434448},{"id":"https://openalex.org/keywords/major-late-promoter","display_name":"major late promoter","score":0.6510000228881836},{"id":"https://openalex.org/keywords/transgene-expression","display_name":"transgene expression","score":0.5699999928474426},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.5699999928474426},{"id":"https://openalex.org/keywords/cd4-t-cells","display_name":"CD4+ T cells","score":0.8610000014305115},{"id":"https://openalex.org/keywords/cytokine-production","display_name":"cytokine production","score":0.6819999814033508},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.699999988079071}],"concepts":[{"id":"https://openalex.org/C82210918","wikidata":"https://www.wikidata.org/wiki/Q1560099","display_name":"Oncolytic virus","level":3,"score":0.8813202381134033},{"id":"https://openalex.org/C956191","wikidata":"https://www.wikidata.org/wiki/Q930144","display_name":"Polyclonal antibodies","level":3,"score":0.6253690719604492},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5390346646308899},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.47008419036865234},{"id":"https://openalex.org/C3020616263","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Tumor cells","level":2,"score":0.4494655728340149},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.44535237550735474},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.36021602153778076},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34523266553878784},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2769947052001953},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.12810611724853516}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2017-5098","doi":"https://doi.org/10.1158/1538-7445.am2017-5098","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2017-5098","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2947569492","https://openalex.org/W4251557812","https://openalex.org/W2566593491","https://openalex.org/W2900257115","https://openalex.org/W2617253673","https://openalex.org/W2476510264","https://openalex.org/W4391309876","https://openalex.org/W4393094870","https://openalex.org/W2246604805","https://openalex.org/W4388081525"],"abstract_inverted_index":{"Abstract":[0],"NG-348":[1,80,135,167,220,277,291,328,342,376],"is":[2,55,63,169,377],"a":[3,8,21,29,92,303,383,415],"transgene-modified":[4],"variant":[5],"of":[6,23,99,134,145,161,181,187,208,236,251,267,287,326,338,350,431,437],"enadenotucirev,":[7],"chimeric":[9],"oncolytic":[10,261,329,417],"group":[11],"B":[12],"adenovirus":[13],"with":[14,65,74,211,276,313,382],"potent":[15,346,426],"and":[16,37,59,91,117,196,228,243,249,334,427],"selective":[17,428],"anti-tumor":[18,374],"activity":[19,62,423],"against":[20],"range":[22],"epithelial":[24],"cancer":[25,45],"cells.":[26],"Enadenotucirev":[27],"has":[28,38,292],"blood":[30],"stability":[31],"profile":[32],"that":[33,51,219,320],"enables":[34],"systemic":[35],"dosing":[36],"been":[39,294],"administered":[40],"intravenously":[41],"to":[42,57,124,184,190,260,281,296,323,367,371,389,420],"over":[43],"90":[44],"patients.":[46],"These":[47],"studies":[48],"have":[49,217],"demonstrated":[50,233],"IV":[52],"dosed":[53],"enadenotucirev":[54],"delivered":[56],"tumors":[58],"subsequent":[60],"virus":[61,147,168,174,191,330,369,418],"associated":[64],"CD8+":[66],"T-cell":[67,113,151,252,339],"infiltration":[68],"in":[69,85,155,165,200,289,300,309,354,365,379,391],"tumor":[70,137,157,194,213,222,254,305,324,364],"cell":[71,214,255],"nests,":[72],"consistent":[73],"immune":[75,152],"stimulation":[76],"within":[77],"the":[78,100,132,139,143,146,156,166,172,182,185,201,264,355,363,368,425,438],"tumor.":[79],"encodes":[81],"two":[82],"immunomodulatory":[83],"proteins":[84,110,183],"its":[86],"genome:":[87],"full-length":[88],"human":[89,209,212,269,298,304,314],"CD80,":[90],"membrane":[93,109],"anchored":[94],"single":[95],"chain":[96],"variable":[97],"fragment":[98],"mouse":[101],"anti-human":[102],"CD3\u03f5":[103],"monoclonal":[104],"antibody":[105],"OKT3.":[106],"Together":[107],"these":[108,317],"provide":[111],"both":[112,162,226],"receptor":[114],"(signal":[115,119],"1)":[116],"costimulatory":[118],"2)":[120],"activation":[121,237,286,349,430],"signals":[122],"required":[123],"polyclonally":[125],"activate":[126,225,297],"tumor-infiltrating":[127,432],"T-cells.":[128,230],"When":[129],"expressed":[130],"on":[131],"surface":[133,186],"infected":[136,221],"cells":[138,188,202,223,271],"transgenes":[140,163],"therefore":[141,344],"enhance":[142],"potency":[144],"by":[148,171,234,257,263],"driving":[149],"local":[150],"responses":[153],"selectively":[154,332],"microenvironment.":[158],"The":[159],"expression":[160,180,199,239,284],"encoded":[164],"controlled":[170],"endogenous":[173],"major":[175],"late":[176],"promoter.":[177],"This":[178,231],"restricts":[179],"permissive":[189],"infection":[192],"(i.e.":[193],"cells)":[195],"prevents":[197],"off-target":[198],"from":[203],"healthy":[204],"tissues.":[205],"Using":[206],"co-cultures":[207],"T-cells":[210,288,299,351,433],"lines,":[215],"we":[216],"shown":[218,295],"potently":[224],"CD4":[227],"CD8":[229],"was":[232],"analysis":[235],"marker":[238],"(CD25,":[240],"CD69),":[241],"intracellular":[242],"secreted":[244],"cytokines":[245],"(IL-2,":[246],"TNF,":[247],"IFN\u03b3)":[248],"induction":[250],"mediated":[253],"death":[256,262],"apoptosis":[258],"(prior":[259],"virus).":[265],"Treatment":[266],"different":[268],"non-tumor":[270],"(e.g.":[272],"fibroblasts,":[273],"T-cells,":[274],"PBMCs)":[275],"did":[278],"not":[279],"lead":[280],"transgene":[282],"protein":[283],"or":[285],"co-cultures.":[290],"also":[293],"vivo,":[301],"using":[302],"xenograft":[306],"model":[307],"system":[308],"immunodeficient":[310],"mice":[311],"reconstituted":[312],"PBMCs.":[315],"Collectively":[316],"data":[318],"indicate":[319],"following":[321],"delivery":[322],"tissues":[325],"patients,":[327],"can":[331],"replicate":[333],"express":[335],"it\u2019s":[336],"payload":[337],"activating":[340],"ligands.":[341],"should":[343],"stimulate":[345],"antigen-independent,":[347],"polyclonal":[348,429],"already":[352],"present":[353],"tumor,":[356],"as":[357,359],"well":[358],"those":[360],"recruited":[361],"into":[362],"response":[366],"infection,":[370],"drive":[372],"effective":[373],"immunity.":[375],"currently":[378],"preclinical":[380],"development":[381],"first":[384],"phase":[385],"I":[386],"study":[387],"planned":[388],"initiate":[390],"Q4":[392],"2017.":[393],"Citation":[394],"Format:":[395],"Brian":[396],"R.":[397],"Champion,":[398],"Matthieu":[399],"Besneux,":[400],"Nalini":[401],"Marino,":[402],"Darren":[403],"Plumb,":[404],"Prithvi":[405],"Kodialbail,":[406],"Sam":[407],"Illingworth,":[408],"Rochelle":[409],"Lear,":[410],"Alice":[411],"C.":[412],"Brown.":[413],"NG-348:":[414],"novel":[416],"designed":[419],"mediate":[421],"anti-tumour":[422],"via":[424],"[abstract].":[434],"In:":[435],"Proceedings":[436],"American":[439],"Association":[440],"for":[441],"Cancer":[442,455],"Research":[443],"Annual":[444],"Meeting":[445],"2017;":[446],"2017":[447],"Apr":[448],"1-5;":[449],"Washington,":[450],"DC.":[451],"Philadelphia":[452],"(PA):":[453],"AACR;":[454],"Res":[456],"2017;77(13":[457],"Suppl):Abstract":[458],"nr":[459],"5098.":[460],"doi:10.1158/1538-7445.AM2017-5098":[461]},"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-08-08T00:00:00"}